Drug Profile
ABT 614
Alternative Names: ABT-614Latest Information Update: 10 Feb 2014
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class Drug withdrawal therapies
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Substance-related disorders
Most Recent Events
- 10 Feb 2014 No development reported - Phase-I for Substance-related disorders in Canada (unspecified route)
- 10 Feb 2014 No development reported - Phase-I for Substance-related disorders in USA (unspecified route)
- 01 Aug 2009 Phase-I clinical trials in Substance-related disorders in USA (unspecified route)